This is the most important round of funding ever carried out in France by a biotech for a first fundraising.
The French company Mnemo Therapeutics has raised 75 million euros under the aegis of Sofinnova Partners, one of the main European funds specializing in health, and the New Yorker Casdin Capital, joined by several international investors (Redmile, Emerson Collective , Alexandria Venture Investments).
Read also:
Can France become a pharmaceutical power again?
Created in 2019, Mnemo specializes in cell therapy for the treatment of cancer.
"These are real breakthrough innovations discovered by world-renowned researchers,"
enthuses Antoine Papiernik, head of Sofinnova Partners.
The objective is to fund the company for the next two and a half years until the launch of its clinical trials. ”
Mnemo was born from a transatlantic collaboration between a French researcher from Argentina officiating at the Institut Curie, Dr Sebastian Amigorena, and a French emigrated to the United States,
This article is for subscribers only.
You have 71% left to discover.
To cultivate your freedom is to cultivate your curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
